Spyre Therapeutics, Inc. (SYRE) intrinsic value & 10-year financials
Spyre Therapeutics, Inc. (SYRE) has a Graham intrinsic value of $651.93 per share. At $79.90 on Oct 17, 2026, the stock trades 88% below that value. Over the last 10 fiscal years revenue shrank 21.0% a year to $0, with an average return on invested capital of 13.3%.
- Graham intrinsic value
- $651.93
- Share price (Oct 17, 2026)
- $79.90
- Price vs Graham value
- 88% below
- Market cap
- $551.1M
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- -21.0%
- ROIC (10-yr avg)
- 13.3%
- Free cash flow (FY2025)
- —
SYRE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$155.2M | — | — | — | -34.0% |
| FY2024 | $0 | -$208.0M | — | -$157.4M | — | 4276.5% |
| FY2023 | $886.0K | -$338.8M | -$49.12 | -$99.9M | -27348.0% | -3326.0% |
| FY2022 | $2.3M | -$83.8M | -$0.99 | -$80.2M | -3640.2% | -182.3% |
| FY2021 | $18.7M | -$65.8M | -$1.00 | -$54.3M | -350.3% | -102.3% |
| FY2020 | $0 | -$80.9M | -$1.52 | -$80.1M | — | -162.2% |
| FY2019 | $0 | -$78.3M | — | -$67.2M | — | -176.3% |
| FY2018 | $3.9M | -$44.3M | — | -$32.6M | -1169.3% | -77.2% |
| FY2017 | $5.2M | -$27.2M | — | -$25.2M | -531.7% | -48.9% |
| FY2016 | $4.6M | -$21.7M | — | -$19.1M | -473.3% | -34.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Spyre Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Spyre Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -29.3% ROIC.
Spyre Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Spyre Therapeutics, Inc. is modeled at -21.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $651.93 per share.